Column-Bonds eye Q4 salvation in another year to forget: McGeever
Stick it out, double down, or cut your losses?
Lilly eyes targeted cancer therapies with $1.4 billion Point Biopharma deal
(Reuters) -Eli Lilly and Co will buy Point Biopharma Global for $1.4 billion, the companies said on Tuesday, gaining access to experimental therapies that enable precise targeting of cancer.
Why a rout in government bonds is worrying
The world's biggest bond markets are in the throes of another rout as a new era of higher for longer interest rates takes hold.
Eli Lilly to buy cancer-focused Point Biopharma for $1.4 billion
(Reuters) -Eli Lilly and Co will buy cancer therapy developer Point Biopharma Global for $1.4 billion, the companies said on Tuesday.
Marketmind: This Fed's not for turning
A look at the day ahead in U.S. and global markets by Mike Dolan
Search
Latest Articles
-
China receives US equipment to make advanced chips despite new rules - report
-
China receives US equipment to make advanced chips despite new rules-report
-
U.S. Treasury yields have peaked, say strategists for fourth straight month: Reuters poll
-
Google's expert in US antitrust trial defends billions paid to device makers
-
Post-strike Hollywood rushes to get film, TV sets humming